Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer WILMINGTON, Del.--(BUSINESS WIRE)-- ...

DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY ® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...

Datroway received FDA accelerated approval for EGFR-mutated NSCLC after progression on EGFR-targeted therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall response rate and a ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. The FDA has greenlighted the drug, datopotamab ...

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic ...

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population If approved, DATROWAY ...

How Does Datroway Work for Breast Cancer? Datroway is a type of medicine known as an antibody drug conjugate (ADC). The ADC is designed to deliver medicine directly to the cancer cells and is made up ...

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY®(datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment ...